Time on boards
- Boards served
- 3
- Current seats
- 3
- Board service
- 9 years
- Director since
- 2023
9 years of board service in total across 3 boards, counting each seat separately. Longest: Halozyme Therapeutics Inc., 3 years.
Halozyme Therapeutics Inc.
Director
Aprea Therapeutics Inc.
Director
ADC Therapeutics SA
Director
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
ADC Therapeutics SA June 1, 202697.2%
-
Aprea Therapeutics Inc. June 5, 202596.7%
-
ADC Therapeutics SA June 3, 202594.6%
-
ADC Therapeutics SA June 13, 202497.1%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jun 16, 2026 | Aprea Therapeutics Inc. | Grant or award | +3,135 | — | — |
| Jun 3, 2026 | ADC Therapeutics SA | Shares withheld for tax | −12,600 | $3.08 | $38,808 |
| Jun 1, 2026 | ADC Therapeutics SA | Grant or award | +45,000 | — | — |
| Jun 13, 2025 | ADC Therapeutics SA | Shares withheld for tax | −12,600 | $3.58 | $45,108 |
| Jun 5, 2025 | Aprea Therapeutics Inc. | Grant or award | +1,045 | — | — |
| Jun 3, 2025 | ADC Therapeutics SA | Grant or award | +40,000 | — | — |
| Jun 17, 2024 | ADC Therapeutics SA | Open-market sale | −6,995 | $2.89 | $20,216 |
| Jun 13, 2024 | ADC Therapeutics SA | Grant or award | +40,000 | — | — |
| May 5, 2023 | Halozyme Therapeutics Inc. | Grant or award | +8,065 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.